Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 401 - 450 out of 111,695

Document Document Title
WO/2016/037592A1
Disclosed are an aminosulfonyl compound represented by general formula I or a tautomer, enantiomer, racemate or pharmaceutically acceptable salt thereof, a preparation method therefor, a pharmaceutical composition and a use thereof. The ...  
WO/2016/039339A1
 The purpose of the present invention is to provide a drug that can promote the growth of oligodendrocyte precursor cells, and effectively prevent or treat demyelinating disease. FGF21 acts to promote the growth of oligodendrocyte prec...  
WO/2016/039660A1
The present invention relates to medicine, and more particularly to pharmacology and psychiatry, and can be used in the manufacture of drugs for treating treatment-resistant forms of schizophrenia. To this end, it is proposed to use the ...  
WO/2016/040789A1
The present invention is directed to compounds of Formula (I): Methods of making the compounds of Formula I are also described. The invention also relates to pharmaceutical compositions comprising compounds of Formula (I). Methods of usi...  
WO/2016/040358A1
Pharmaceutical compositions and methods are provided to treat headache, headache-associated symptoms, or adverse effects associated with triptan administration.  
WO/2016/039359A1
The present invention relates to: a terpenoid derivative which is capable of activating a Keap1/Nrf2/ARE signaling pathway and has an excellent anti-inflammatory activity and an excellent cell-protecting activity; and a sustained-release...  
WO/2016/039398A1
The present invention relates to a neuroprotective agent and addresses the problem of providing a medicine for preventing and/or treating neurological disease. The problem is solved by using a compound, which has a 2-aminobenzamide struc...  
WO/2016/040322A1
Described herein are methods of treating tremor, e.g., essential tremor; depression, e.g., postpostum depression; and anxiety disorder, the method comprising administering to a human subject suffering from tremor, e.g., essential tremor;...  
WO/2016/039393A1
The purpose of the present invention is to provide a method for high-yield, inexpensive, and safe industrial production of a lacosamide having high optical purity. The present invention addresses said issue by providing a method for high...  
WO/2016/039462A1
The present invention addresses the problem of providing a method for obtaining Schwann cells directly (by direct reprogramming) without going via pluripotent stem cells such as ES cells, iPS cells or the like. As a means for solving thi...  
WO/2016/038500A1
The present invention relates to solid forms of 6-carboxy-2-(3,5-dichlorophenyl)- benzoxazole and to methods for their preparation. The invention is also directed to pharmaceutical compositions containing at least one solid form and to t...  
WO/2016/038379A1
The invention relates to pharmaceutical uses of compounds of formula (II). Particular aspects of the invention relate to the use of those compounds in treating, preventing or ameliorating a seizure-related disorder, bipolar disorder, man...  
WO/2016/040643A1
Provided herein are Amyotrophic lateral sclerosis (ALS) biomarkers and methods of using these ALS biomarkers to diagnose and treat ALS.  
WO/2016/039408A1
The present invention addresses the problem of providing a compound that has excellent RORγt-inhibiting effects and is useful as a preventive or therapeutic agent for psoriasis, inflammatory bowel disease, ulcerative colitis, Crohn's di...  
WO/2016/038616A1
The present invention provides pharmaceutical compositions comprising at least one NMDA receptor antagonist for use in treating neuropathic forms of Gaucher Disease (nGD).  
WO/2016/037587A1
MitoCells treated with angelica extract is provided. Also provided is a pharmaceutical composition comprising the MitoCells. The pharmaceutical composition can significantly achieve the goal for treating degenerative neurological disease.  
WO/2016/040930A1
The present disclosure is related to methods of treating agitation and/or aggression and/or associated symptoms in subjects with dementia, including, dementia associated with Alzheimer's disease. The method includes administering to a su...  
WO/2016/039163A1
Provided is a hepatocyte growth factor (HGF) preparation such as an injection that is usable for treating central nervous diseases by intramedullary administration, intraventricular administration, administration into spinal parenchyma o...  
WO/2016/039358A1
The present invention pertains to a compound that has an excellent retinoic acid receptor-related orphan receptor γt inhibitory effect, or a pharmaceutically acceptable salt thereof. Provided is a compound represented by general formula...  
WO/2016/039977A1
The present invention is directed to compounds of Formula (I), which includes enantiomer and diasteromers thereof. The invention also relates to pharmaceutical compositions comprising compounds of Formula (I). Methods of making and using...  
WO/2016/039448A1
This invention provides a new aromatic carboxylic acid amide compound that has a TRPM8 blocking effect and is useful as a medicine. Specifically, this invention provides an aromatic carboxylic acid amide compound represented by formula (...  
WO/2016/040932A1
Described herein is a novel application involving the use of therapeutic or cosmetic formulations of botulinum toxin involving an increase and enhancement of longevity in human subjects. The inventors are physicians who have used this ag...  
WO/2016/034145A1
A composition of (6S)-5-methyl tetrahydrofolic acid or a salt thereof as well as the preparation therefor and an application thereof. The content of the (6S)-5-methyl tetrahydrofolic acid or the salt thereof is not less than 98.0%, the c...  
WO/2016/035182A1
[Problem] The purpose of the present invention is to provide a composition that is a ginsenoside composition derived from medicinal ginseng and that is particularly useful as a composition for oral use. [Solution] Provided is a compositi...  
WO/2016/035820A1
 Provided are: a centrally-acting peptide derivative having a central action portion, a transmembrane sequence portion, and an endosome escape portion; and a pharmaceutical composition including the same.  
WO/2016/034851A1
Provided is an incretin, or analogue thereof, an incretin receptor agonist, an incretin enhancer, or any combination thereof, for use in a method of reducing elevated intracranial pressure (ICP) in a subject. Methods of reducing elevated...  
WO/2016/037071A3
The present invention relates to RNAi constructs with improved tissue and cellular uptake characteristics and methods of use of these compounds in dermal applications.  
WO/2016/037026A1
Cyclohexylethyl substituted diaza- and triaza-tricyclic compounds, such as e.g. 5-(2-(cyclohexyl)ethyl)-5H-imidazo[5,1-a]isoindole, 1-Cyclohexyl-2-[4,6,10-triazatricyclo[6.4.0.0^[2,6]]dodeca-1 (8),2,4,9,11-pentaen-7-yl]ethan-1-ol derivat...  
WO/2016/036719A1
Provided are methods for slowing, halting, and reversing gray matter atrophy and progression of disability in certain neurodegenerative diseases, including multiple sclerosis using estrogen, alone or in combination with another agent.  
WO/2016/037106A1
The present invention provides compounds useful as inhibitors of Ca2+/calmodulin-dependent protein kinase (CaMKII), compositions thereof, and methods of using the same.  
WO/2016/036403A1
This document provides methods and materials related to treating subjects having specific genetic variations associated with neurological disorders such as Parkinson's disease.  
WO/2016/036724A1
The present invention provides new compositions and methods for treating and/or reversing organophosphate intoxication, manifested by both cholinergic and non-cholinergic crisis, in a mammal resulting from exposure to organophosphate com...  
WO/2016/036308A1
A pharmaceutical gel composition for intra-intestinal administration comprises (i) a dopamine replacement agents, (ii) a dopamine decarboxylase inhibitor (DDI), and (iii) a COMT inhibitor.  
WO/2016/036619A1
Embodiments of the invention relate to the treatment of sleep disturbances in individuals with Smith-Magenis Syndrome (SMS).  
WO/2016/034882A1
The present invention relates to compounds that are inhibitors of the orexin-1 receptor. The compounds have the structural formula I defined herein. The present invention also relates to processes for the preparation of these compounds, ...  
WO/2016/034079A1
The present invention relates to a pharmaceutical preparation of a compound of formula (I) or stereoisomer, pharmaceutically acceptable salt, prodrug thereof, and a novel method for general anesthesia or sedative for mammals. Also provid...  
WO/2016/036721A1
The present invention relates to treatment of neurological diseases such as multiple sclerosis (MS) and Alzheimer's disease, using an estrogen receptor beta (ΕΚβ) ligand.  
WO/2016/033774A1
Provided in the present invention are a β-lamella blocking peptide used for preventing and/or treating Alzheimer's disease, and the use thereof for preventing and/or treating Alzheimer's disease. The amino acid sequence of the β-lamell...  
WO/2016/032249A1
The present invention relates to a pharmaceutical composition and a food composition containing Vaccinium bracteatum Thunb. extract or a fraction thereof as an active ingredient for preventing, treating or ameliorating neuroinflammation ...  
WO/2016/030306A1
The present invention relates to a compound of formula (I) wherein R1/R2 are independently from each other hydrogen or halogen; L is a bond, -NH-, -C(O)NH-, -NHC(O)- or NHC(O)NH-; R is hydrogen, lower alkyl, cycloalkyl, benzyl, phenyl or...  
WO/2016/029454A1
Provided are quinoline carboxamide and quinoline carbonitrile compounds of formula (I) or a pharmaceutically acceptable salt thereof, wherein R 1, R 2, L, X 1, X 2, and X 3, are as defined herein. The compounds of the invention, and phar...  
WO/2016/032569A1
Provided herein are quinolines, e.g., a compound of Formula (I) or (IB), pharmaceutical compositions thereof, and methods of their use for treating, preventing, or ameliorating one or more symptoms of an endoplasmic reticulum stress-caus...  
WO/2016/030345A1
The invention relates to a product that comprises a compound of formula (1-01) to (1-47) and a compound of formula (2-01) to (2-26),or their pharmaceutically or veterinary acceptable salts thereof, or any stereoisomers either of the comp...  
WO/2016/029669A9
The present invention relates to a photo-hexyl ether compound, and a pharmaceutical composition and usage thereof. Particularly, the present invention relates to 2(4)-(1-hexyloxyethyl)-6,7-dipropionate-1,3,5,8-tetramethyl- 4(2)-vinylporp...  
WO/2016/031987A1
A compound represented by any of formulas (Ia)-(Ic) or formula (II), or a pharmaceutically acceptable salt thereof. (In the formulas, R1, R2, R3, R4a, R4c, R5, R15, ring A, X1, and X2 are as defined in the specification.)  
WO/2016/030444A1
The present invention provides a novel chromone oxime derivative of formula (I), which is a modulator of nervous system receptors sensitive to glutamate and, furthermore, presents an advantageously high brain penetration upon oral admini...  
WO/2016/033326A3
Disclosed herein are methods for reducing or arresting an increase in a Neuropathy Impairment Score (NIS) or a modified NIS (mNIS+7) in a human subject by administering an effective amount of a transthyretin (TTR)-inhibiting composition.  
WO/2016/033100A1
In certain aspects, the invention provides a method for treating a disease or condition in a subject, the method comprising co-administering to a subject in need thereof a therapeutically effective amount of at least one ULK1-inhibiting ...  
WO/2016/031742A1
[Problem] To provide a medicine useful for the amelioration of paresthesia induced by peripheral nerve disorders. [Solution] An extract from a plant belonging to the genus Plantago (e.g., a Plantago seed, a Plantago herb) is useful for t...  
WO/2016/029669A1
The present invention relates to a photo-hexyl ether compound, and a pharmaceutical composition and usage thereof. Particularly, the present invention relates to 2(4)-(1-hexyloxyethyl)-6,7-dipropionate-1,3,5,8-tetramethyl- 4(2)-vinylporp...  

Matches 401 - 450 out of 111,695